Search - tctmd.com

Displaying 101 - 120 of 218

Sort: Relevancy | Date

News Daily News

SCAAR: Menor Riesgo de Trombosis Precoz, Tardía del Stent con Nuevos SLF frente a SMD en el Manejo de Cuadros de STEMI

Yael L. Maxwell

July 03, 2014

News Daily News

SCAAR: Lower Risk of Early, Late Stent Thrombosis with Newer DES vs BMS in STEMI

Yael L. Maxwell

July 03, 2014

News Features

Renal Denervation 2.0: Laying Out the Road to Recovery from Symplicity HTN-3

June 24, 2014

News Features

Denervación Renal 2.0: Marcando el Camino de la Recuperación Tras el Symplicity HTN-3

June 24, 2014

News Features

Renal Denervation 2.0: Assessing the Failure of a Pivotal Trial

June 18, 2014

News Daily News

BRAVE 4: Prasugrel Plus Bivalirudin Fails to Mitigate Stent Thrombosis in STEMI Patients

May 14, 2014

News Daily News

Many Patients Referred for Renal Denervation Improve with Medication Adjustment

May 12, 2014

News Daily News

Renal Denervation Shows Promise in Patients Refractory to Stenting

L.A. McKeown

May 02, 2014

News Daily News

Registry: DAPT Discontinuation Less Associated With Second-Gen DES Thrombosis Compared to First-Gen DES

L.A. McKeown

April 11, 2014

News Conference News ACC 2014

ACC/i2 2014: Cardiologists Carefully Consider TAVR, Renal Denervation

Yael L. Maxwell

April 03, 2014

News Conference News ACC 2014

CHAMPION PHOENIX Analysis: Cangrelor Reduces Early Stent Thrombosis, Suggesting Mortality Benefit

April 02, 2014

News Conference News ACC 2014

Renal Denervation Fails to Meet Efficacy Endpoints Compared with Placebo Procedure

Yael L. Maxwell

March 29, 2014

News Industry News

ANTI-CLOTTING AGENT HELPS REDUCE THE INCIDENCE AND IMPACT OF STENT THROMBOSIS DURING PERCUTANEOUS CORONARY INTERVENTION

March 27, 2014

News Daily News

DAPT Interruption At Least 1 Month After ZES Implantation Appears Safe

Yael L. Maxwell

February 17, 2014

News Industry News

Medtronic Announces U.S. Renal Denervation Pivotal Trial Fails to Meet Primary Efficacy Endpoint While Meeting Primary Safety Endpoint

January 08, 2014

Presentation TCT 2013

The Case for Intravenous Cangrelor as the Preferred ADP Antagonist to Support Primary PCI

Presenter: Deepak Bhatt

October 30, 2013

Presentation TCT 2013

Important Lessons from SIMPLICITY HTN-3 (Inclusion Criteria, Site Selection, and Study Endpoints): What I Would Do Differently Next Time?

Presenter: Deepak Bhatt

October 30, 2013

Presentation

Welcome and Introductions/Pre-test

Presenter: Deepak Bhatt

October 29, 2013

Presentation

Perspectives in Individualized Antiplatelet Therapy: Comorbidities and Characteristics

Presenter: Deepak Bhatt

October 29, 2013

News Industry News

Anti-Clotting Agent Helps Reduce the Risk of Intraprocedural Events during Percutaneous Coronary Intervention

October 28, 2013

Advertisement

SCAAR: Menor Riesgo de Trombosis Precoz, Tardía del Stent con Nuevos SLF frente a SMD en el Manejo de Cuadros de STEMI

SCAAR: Lower Risk of Early, Late Stent Thrombosis with Newer DES vs BMS in STEMI

Renal Denervation 2.0: Laying Out the Road to Recovery from Symplicity HTN-3

Denervación Renal 2.0: Marcando el Camino de la Recuperación Tras el Symplicity HTN-3

Renal Denervation 2.0: Assessing the Failure of a Pivotal Trial

BRAVE 4: Prasugrel Plus Bivalirudin Fails to Mitigate Stent Thrombosis in STEMI Patients

Many Patients Referred for Renal Denervation Improve with Medication Adjustment

Renal Denervation Shows Promise in Patients Refractory to Stenting

Registry: DAPT Discontinuation Less Associated With Second-Gen DES Thrombosis Compared to First-Gen DES

ACC/i2 2014: Cardiologists Carefully Consider TAVR, Renal Denervation

CHAMPION PHOENIX Analysis: Cangrelor Reduces Early Stent Thrombosis, Suggesting Mortality Benefit

Renal Denervation Fails to Meet Efficacy Endpoints Compared with Placebo Procedure

ANTI-CLOTTING AGENT HELPS REDUCE THE INCIDENCE AND IMPACT OF STENT THROMBOSIS DURING PERCUTANEOUS CORONARY INTERVENTION

DAPT Interruption At Least 1 Month After ZES Implantation Appears Safe

Medtronic Announces U.S. Renal Denervation Pivotal Trial Fails to Meet Primary Efficacy Endpoint While Meeting Primary Safety Endpoint

The Case for Intravenous Cangrelor as the Preferred ADP Antagonist to Support Primary PCI

Important Lessons from SIMPLICITY HTN-3 (Inclusion Criteria, Site Selection, and Study Endpoints): What I Would Do Differently Next Time?

Welcome and Introductions/Pre-test

Perspectives in Individualized Antiplatelet Therapy: Comorbidities and Characteristics

Anti-Clotting Agent Helps Reduce the Risk of Intraprocedural Events during Percutaneous Coronary Intervention

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content